<scp>ABO</scp>‐Blood Group Associates With Survival Outcomes in Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy
BGO associates with favorable survival in patients with NSCLC receiving pembrolizumab monotherapy, but not in patients with chemo-immunotherapy or chemotherapy. Further validation of this promising strategy for personalized decision-making is warranted.
Authors
- Smiths Lueong (ORCID: https://orcid.org/0000-0002-2776-6706)
- Martin Metzenmacher (ORCID: https://orcid.org/0000-0001-5395-9010)
- Stefan Kasper (ORCID: https://orcid.org/0000-0002-5947-8733)
- Isabel Virchow (ORCID: https://orcid.org/0000-0001-6997-1161)
- Peter A. Horn (ORCID: https://orcid.org/0000-0003-0901-3484)
- Bastian Mende
- Martin Schüler (ORCID: https://orcid.org/0000-0002-2166-3394)
- Gregor Zaun (ORCID: https://orcid.org/0000-0002-3813-6961)
- Yasmin Zaun
- Thomas Hilser
- Halime Kalkavan (ORCID: https://orcid.org/0000-0002-0090-4080)
- Michael Pogorzelski
- Julius Keyl (ORCID: https://orcid.org/0000-0002-5617-091X)
- Marcel Wiesweg (ORCID: https://orcid.org/0000-0002-9698-9559)
- Sarah Theurer (ORCID: https://orcid.org/0000-0002-2704-6469)
- Franziska Certa
Institutions
- National Center for Tumor Diseases (DE)
- Essen University Hospital (DE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Thoracic Cancer
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1111/1759-7714.70037
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Novocure
- Incyte
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Deutsche Krebshilfe
- Universität Duisburg-Essen
- Servier
- Ipsen
- Medizinische Fakultät, Universität Duisburg-Essen
- Daiichi Sankyo Europe